Eversheds Sutherland advises Humanwell Healthcare Group on the Acquisition of the assets of Paion AG and Paion Deutschland GmbH including shares in Paion Holdings UK
13. März 2024
Eversheds Sutherland advises Humanwell Healthcare Group on the Acquisition of the assets of Paion AG and Paion Deutschland GmbH including shares in Paion Holdings UK13. März 2024 Humanwell Healthcare (Group) Co. Ltd. is a leading Chinese listed pharmaceutical company mainly engaged in the development, manufacture and distribution of drugs in the fields of anaesthesia and analgesics, gynaecological diseases, central nervous system, dermatology and respiratory diseases as well as other drugs used in hospitals. Humanwell has more than 520 approved drugs worldwide and 350 drug candidates in the pipeline. In 2022, Humanwell generated sales of USD 3.4 billion and a net profit of USD 0.38 billion. Humanwell distributes its products mainly in China, Africa and the USA and exports its products to more than 50 countries. "The sale of PAION to Humanwell is a success for the insolvency process, as the majority of jobs have been saved and the full and comprehensive continuation of business operations has been secured. I am confident that PAION will be positioned for the future under the umbrella of Humanwell. This result is due to the committed and professional cooperation with managing director Tilmann Bur and the other parties involved in the proceedings," says Dr. Mark Boddenberg, who is accompanying the proceedings as the court-appointed insolvency administrator. Publikationen
News
Events und Trainingslegal updates 20. November 2026 COP31: Enhancing Implementation - Revised draft seeks consensus amid compet... legal updates 20. November 2026 Implementation of the EU Pay Transparency Directive: New development in Spa... legal updates 19. November 2026 COP31: People and progress in focus as negotiations reach a critical stage legal updates 19. November 2026 Learning from experience | Mentoring for Alumni |